Pressure Ulcer Biologics: Clinical Decision Framework

Clinical Context

Hospital-acquired pressure injuries (HAPIs) affect over 2.5 million patients annually in the United States, with aggregate direct costs estimated at $26.8 billion. Despite prevention protocols, Stage III and IV pressure injuries persist as a significant clinical challenge in acute care, long-term care, and skilled nursing settings. The Wound Healing Society (WHS) 2023 guideline update reinforces that deep pressure injuries carry a poor prognosis for spontaneous closure: full-thickness wounds extending into subcutaneous tissue, muscle, or bone lack the intrinsic regenerative capacity of superficial injuries and often require advanced intervention.

The operative clinical question is not whether standard of care (SOC) — offloading, debridement, moisture balance, infection control — applies. It does. The question is when SOC alone is insufficient and adjunctive biologic therapy may be considered. This article provides a stage-specific decision framework grounded in NPIAP criteria, WHS guidelines, published evidence, and current CMS coverage parameters.

        Disclaimer: Standard of care — including pressure redistribution, sharp debridement, infection control, and nutritional optimization — remains the foundation of pressure injury management. Biologics are adjunctive and do not replace SOC. No claim of superiority over other skin substitutes is implied or stated. Coverage policies vary by Medicare Administrative Contractor (MAC). Individual results may vary.
      

Staging and Risk Stratification

Accurate staging per the National Pressure Injury Advisory Panel (NPIAP) system is the prerequisite for any biologic escalation decision. Stage III injuries involve full-thickness skin loss with visible adipose tissue; Stage IV injuries extend to fascia, muscle, tendon, or bone. Unstageable injuries — those obscured by slough or eschar — must be debrided to visible depth before staging and treatment planning.

NPIAP Stage	Tissue Depth	Biologic Candidacy
Stage 1	Non-blanchable erythema, intact skin	Not indicated — offloading and skin protection
Stage 2	Partial-thickness skin loss with exposed dermis	Generally not indicated — moisture-retentive dressings suffice
Stage 3	Full-thickness skin loss; adipose visible	May be considered after ≥4 weeks of optimized SOC without ≥30% area reduction
Stage 4	Full-thickness tissue loss; fascia, muscle, or bone exposed	May be considered after wound bed preparation and infection clearance
Unstageable	Full-thickness obscured by slough or eschar	Defer until debridement permits accurate staging and wound bed assessment

The Braden Scale for Predicting Pressure Sore Risk — comprising sensory perception, moisture, activity, mobility, nutrition, and friction/shear — is a validated risk-assessment tool but does not directly guide biologic treatment decisions. Its role is identifying patients at risk for developing new or worsening pressure injuries during treatment, which informs offloading and repositioning plans that must remain in place throughout any biologic therapy course.

Step 1: Optimized Standard of Care

Before escalation to biologic therapy, clinicians should confirm that each of the following has been implemented and sustained for a minimum of 2–4 weeks:

Offloading and pressure redistribution: Specialized support surfaces (low-air-loss or alternating-pressure mattresses), scheduled repositioning (minimum every 2 hours), heel suspension devices when indicated. Per the WHS 2023 guideline, pressure relief is non-negotiable — adjunctive therapies layered onto inadequate offloading will not produce closure.
Sharp debridement: Removal of necrotic tissue, slough, and biofilm burden to expose a viable wound bed. Serial debridement at each visit until granulation tissue appears.
Infection control: Assess for local or systemic infection. Obtain quantitative tissue culture or deep swab if cellulitis or osteomyelitis is suspected. Biologics should not be applied to actively infected wounds.
Moisture balance: Absorbent or superabsorbent dressings for high-exudate Stage III/IV wounds; hydrogels or hydrocolloids for drier beds.
Nutritional optimization: Serum albumin ≥3.0 g/dL, prealbumin ≥15 mg/dL. Protein-calorie malnutrition correlates directly with healing failure in pressure injury populations.

        Clinical note: The WHS 2023 guideline emphasizes that a 4-week healing trajectory benchmark — ≥30% wound area reduction — is the strongest predictor of eventual closure for pressure injuries receiving optimized SOC. Wounds below this threshold at 4 weeks are unlikely to heal within 12 weeks with SOC alone and may be considered for adjunctive therapy.
      

Step 2: Biologic Candidacy Assessment

When SOC has been optimized, documented, and sustained without adequate healing progress, amniotic membrane allografts or other biologic skin substitutes may be considered. The following criteria, drawn from published RCT inclusion parameters and WHS guideline recommendations, support escalation:

Factor	Favors Biologic Consideration	Defer or Contraindicate
Stage	Stage III or IV with viable wound bed after debridement	Stage I, II, or unstageable without debridement
Duration on SOC	≥4 weeks with <30% area reduction despite adequate offloading and debridement	<4 weeks or improving trajectory (≥30% reduction)
Wound area	>5 cm² (larger wounds show greater relative benefit in available evidence)	<2 cm² with progressive closure on SOC
Infection status	No clinical signs of infection; negative deep tissue culture (if indicated)	Active cellulitis, osteomyelitis, or purulent drainage
Wound bed	Granulating base with areas of exposed viable tissue; no residual necrotic tissue	Persistent slough, eschar, or non-viable tissue requiring additional debridement
Perfusion	Adequate local perfusion (ABI >0.75 or TBI >0.50)	Critical limb ischemia (ABI <0.4); revascularization needed first
Nutritional status	Serum albumin ≥3.0 g/dL; patient tolerating nutritional support	Severe malnutrition uncorrected; terminal or palliative status with non-healing goal

Step 3: Evidence for Biologics in Pressure Ulcers

The evidence base for biologic skin substitutes in pressure ulcers is smaller than for diabetic foot ulcers or venous leg ulcers, but several studies provide clinically useful data.

Narayan et al., 2025 — Biological Skin Substitutes in Pressure Ulcers

A comparative study of high-purity type I collagen (HPTC) versus dehydrated human amnion/chorion membrane (dHACM) in pressure ulcer management found both modalities superior to SOC alone. The dHACM group showed more rapid granulation tissue formation at 4 weeks. Both groups demonstrated statistically significant wound area reduction compared with SOC controls (p < 0.05). This study is one of the few head-to-head comparisons of biologic categories in a pressure ulcer population.

Cryopreserved amniotic membrane — randomized evidence (PMID 29177171)

A randomized controlled trial of cryopreserved amniotic membrane versus conventional dressing for pressure ulcers reported that complete healing occurred only in the amnion group (p < 0.001). Partial healing was also significantly higher in the treatment arm. The study population comprised Stage III and IV pressure ulcers with a minimum 4-week SOC wash-in period.

        Interpretation: Available evidence suggests that amniotic membrane allografts — in dehydrated or cryopreserved format — may promote wound closure in properly selected Stage III and IV pressure injuries. No trial has demonstrated superiority of one preservation format or biologic category over another in this wound etiology. Product selection should be based on wound characteristics, institutional formulary, and clinician experience.
      

Step 4: CMS Coverage and Documentation Requirements (2026 Q2)

CMS coverage for skin substitutes in pressure ulcer treatment operates within a evolving regulatory landscape. As of 2026 Q2:

The final Local Coverage Determinations (LCDs) for Skin Substitute Grafts for the Treatment of DFUs and VLUs that had been scheduled for January 1, 2026, were withdrawn by CMS in December 2025. These LCDs specifically addressed DFU and VLU coverage and did not directly restrict pressure ulcer indications.
However, the payment reforms for skin substitutes established under the CY 2026 Medicare Physician Fee Schedule remain in effect. Sheet products are reimbursed at a uniform rate of $127.14 per cm² across hospital outpatient, ASC, and physician office settings.
Pressure ulcers fall outside the scope of the withdrawn LCDs, meaning coverage continues under general Medicare reasonable and necessary (R&N) criteria, subject to individual MAC discretion. Providers should verify current local coverage policies with their specific MAC before initiating treatment.

Documentation to support medical necessity for biologic use in pressure ulcers should include:

Wound stage (NPIAP criteria), precise location, dimensions (±photographs with measurement reference)
Duration of SOC prior to escalation, including specific offloading protocol, debridement dates, and dressing regimen
Serial wound measurements at 2-week intervals demonstrating inadequate healing trajectory (<30% area reduction at 4 weeks)
Documentation of debridement adequacy: wound bed description (percentage granulation, fibrin, slough, eschar)
Infection assessment: culture results if taken, absence of cellulitis or osteomyelitis
Nutritional status: serum albumin, prealbumin, and nutritional intervention plan
Product-specific documentation: product name (e.g., AmnioAMP, Rampart), size, quantity, application date, fixation method, secondary dressing
CPT application codes (15271–15278, depending on wound area) and HCPCS product Q-code

        Compliance note: Coverage policies vary by MAC and change frequently. The documentation framework above is intended for preparation purposes and does not guarantee authorization or payment. Verify current local coverage policies before initiating treatment. No claim that amniotic membrane is superior to other skin substitutes is stated or implied.
      

Key Takeaways

Stage III and IV pressure injuries that fail to achieve ≥30% area reduction after 4 weeks of optimized SOC may be candidates for adjunctive biologic therapy with amniotic membrane allografts or other skin substitutes.
NPIAP staging is foundational — unstageable wounds must be debrided to visible depth before treatment planning.
Available evidence, including the Narayan et al. comparative study and cryopreserved amniotic membrane RCT data, supports biologic use in properly selected pressure ulcer populations.
CMS withdrew the planned LCDs for DFU/VLU skin substitutes in December 2025. Pressure ulcer coverage continues under general R&N criteria with MAC-specific variation; CY 2026 payment reforms ($127.14/cm² for sheet products) remain in effect.
Thorough documentation of staging, SOC duration, serial measurements, infection status, and clinical rationale is essential for coverage support.

References

Gould LJ, Alderden J, Aslam R, et al. WHS Guidelines for the Treatment of Pressure Ulcers — 2023 update. Wound Repair Regen. 2023;32(1):6. doi:10.1111/wrr.13130
Narayan N, Ramegowda YH, Raghupathi DS, Chethan S, Gowda S. Biological Skin Substitutes in Pressure Ulcers: High-Purity Type I Collagen-Based Versus Amnion/Chorion Membrane. Cureus. 2025;17(8):e12377520. doi:10.7759/cureus.12377520 (PMCID: PMC12377520)
Grafting with Cryopreserved Amniotic Membrane versus Conventional Dressing in Pressure Ulcers. Wound Repair Regen. 2018;26(Suppl 1):S13-S20. (PMID: 29177171)
Edsberg LE, Black JM, Goldberg M, McNichol L, Moore L, Sieggreen M. Revised National Pressure Ulcer Advisory Panel Pressure Injury Staging System. J Wound Ostomy Continence Nurs. 2016;43(6):585-597. doi:10.1097/WON.0000000000000281
National Pressure Injury Advisory Panel. NPIAP Pressure Injury Stages. Available at: https://cdn.ymaws.com/npiap.com/resource/resmgr/online_store/npiap_pressure_injury_stages.pdf
Centers for Medicare & Medicaid Services. Final Local Coverage Determinations (LCDs) for Certain Skin Substitutes Withdrawn. CMS Newsroom, December 24, 2025. Available at: https://www.cms.gov/newsroom/fact-sheets/upcoming-update-final-local-coverage-determinations-lcds-certain-skin-substitutes
CMS Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). Skin substitute payment rate: $127.14/cm² for sheet products in HOPD, ASC, and physician office settings.
European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. The International Guideline. 2019 (4th Edition).
Braden BJ, Bergstrom N. Clinical utility of the Braden Scale for Predicting Pressure Sore Risk. Decubitus. 1989;2(3):44-51.

Evaluate AmnioAMP or Rampart for Your Pressure Ulcer Protocol

Clinicians interested in advanced amniotic membrane wound biologics for pressure injury management can request product samples and clinical information.

Request samples at nextgenbiologicsusa.com